Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Valeant got into trouble nearly a decade ago after using debt to ...

Gibbons and Venable filed a pair of complaints Wednesday on behalf of Bausch & Lomb involving federal trademark ... Nutriceuticals also sell an eye health dietary supplement called NutriTear ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential ... the steep valuation discount between BLCO and its closest eye care peers,” said analysts from Wells Fargo in a note.

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) and keeping the price target at $23.00. Larry Biegelsen has given his Buy ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times ...

Bausch+Lomb, valued at over $10 billion, is exploring a sale to resolve financial issues tied to its parent, Bausch Health, with $21 billion The eye care giant is projected to generate $4.7 ...

As board-certified dermatologist Dendy Engelman, MD, FACMS, FAAD, previously told Well+Good: “By age 30, ceramide production drops ... to consider eye cream—and the Filorga 5-XP Eye Cream ...

You instantly get a collection of character skins, with even more on the way. There are also some XP boosts and premium currency to add to your account as well, as long as you stay subscribed.

this is a good opportunity for the market to finally realize what we have in Bausch + Lomb. I would keep a close eye on the potential buyout rumors because that is the most obvious means to see an ...

Bausch + Lomb BLCO shares ended the last trading session ... So, make sure to keep an eye on BLCO going forward to see if this recent jump can turn into more strength down the road.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Bausch + Lomb, one of the world’s largest contact lens suppliers, is exploring a sale as a way to clean ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...